Gossamer Bio is a San Diego-based biotech that is readying for an initial public offering – and with a diverse pipeline including potential treatments for a severe type of asthma, pulmonary arterial hypertension and inflammatory bowel disease, this IPO could be particularly appealing to investors. However, despite the promise associated with this biotech, there are also a number of potential problems that prospective investors should be aware of. For more, CLICK HERE.
The five stocks highlighted in today’s article were not big headline-grabbers this earnings season, yet they each had surprisingly positive numbers to report despite recent struggles. As such, the author sees them as some of the season’s “hidden gems” that investors may want to consider. To find out what these five potentially underappreciated stocks are – a telecom giant, a biotech, two apparel names and an aerospace company – CLICK HERE.
A number of conferences have recently taken place where cancer researchers have revealed the latest and most promising developments in the fight against this disease. Today’s article highlights critical advances in two existing cancer therapies – one which allows the immune system to find otherwise invisible tumors and another in which the white blood cells of blood cancer patients are genetically altered so they can better fight the disease – as well as three biotech companies that the author sees as the best pure plays on these advances for investors. To read more, CLICK HERE.
Today’s article notes that it takes almost $1 billion to bring a new drug to market, stifling competition and allowing drug companies to charge Americans exorbitant amounts for the drugs they require. However, new legislation recently signed into law – the 21st Century Cures Act – seeks to streamline the approval process and bring new drugs to market faster, which the author notes “could be a boon for Big Pharma.” So, how can investors profit from this boon? The author highlights two top players in the generic pharmaceutical sector – as well as a biotech ETF that “gives you exposure to potentially huge moves from the little guys” – to consider. To read more, CLICK HERE.
After being weighted down this year by the prospect of a Hillary Clinton administration focused on curbing drug prices, biotechs have seen a recovery since the unexpected victory of Donald Trump, whose campaign rhetoric suggests that he will be friendlier towards the industry. With this reversal of fortunes for the biotech sector, it may be worth considering the four biotech stocks recommended in today’s article, which was written before Trump even pulled off his surprise upset over Clinton. To read about these four biotechs that the author believes have the potential for market-beating gains – including the developer of the first noninvasive test for colorectal cancer – CLICK HERE.